EX-99.1 2 glue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 Newly announced unblinded safety data from MRT-8102 SAD/MAD cohorts continue to support favorable safety/tolerability profile and wide therapeutic window Company plans to initiate multiple Phase 2 studies of MRT-8102, including in patients with elevated CVD-risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 Presented positive interim data from the Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide showing 100% PSA response rate in metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations Phase 2 study initiation of MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations anticipated in Q3 2026 VAV1-directed MGD MRT-6160 advancing toward anticipate…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Monte Rosa Therapeutics, Inc.
GLUENASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On March 17, 2026, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Company context
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.